Abnormal cells can clog blood vessels, leading to severe pain episodes and restricting oxygen delivery to vital organs ...
Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, to treat sickle cell disease (SCD). The trial aims to assess ...